Pharma sector calls for drug prices to build in real-world value

The pharmaceutical industry wants future negotiations on drug pricing to include the extent to which drugs prevent costly hospital stays and details of other societal benefits they generate

Susan Mitchell

Deputy Editor and Health Editor @susmitchellsbp
17th November, 2019
Aidan Lynch: the IPHA president believes price needs to be looked at as an end-to-end cost rather than in isolation Pic: Bryan Meade

The pharmaceutical industry wants future negotiations on drug pricing to include the extent to which drugs prevent costly hospital stays and details of other societal benefits they generate.

Aidan Lynch, general manager of GSK and president of the Irish Pharmaceutical Healthcare Association (IPHA), which represents the industry, said: “If we could look, not just at price in isolation, but at an end-to-end cost, such as bed days and reduced staff required – that type of...

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

Specialist eating disorder unit delayed until at least mid-2022

Updated cost of new children’s hospital still ‘confidential’

Hospital group boards to be disbanded to make way for regional health areas

St Vincent’s set to build new €15m intensive care unit